In news released today, RoosterBio announced the “commercial launch of a new xeno-free version of their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium.” RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
Mesenchymal stem cells (MSC) are now more frequently cited than any other stem cell type within the scientific literature and Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. As a result of increases in MSC research frequency, it is important that companies like RoosterBio develop products to support efficient research processes.
To learn more, view our recent interview with Jon Rowley, RoosterBio’s CEO, or read the full press release issued by RoosterBio.
Designed by RoosterBio Inc: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
Highly efficient bioprocess media systems provide engineered solutions for rapid product development, manufacturing scale up and industrialization of stem cells.
FREDERICK, MD (PRWEB) JUNE 13, 2016 — RoosterBio Inc. announces the commercial launch of a new xeno-free version of their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This xeno-free media formulation extends RoosterBio’s portfolio of bioprocess media engineered to streamline culture processes, minimize processing time, significantly decrease production costs, reduce regulatory burden and simplify the transition into scalable platforms for clinical and commercial adult stem cell manufacturing.
The newly launched High Performance Media XF system is devoid of any xeno-sourced raw materials, and maintains the economic and production efficiency of RoosterBio’s original, customer-trusted High Performance Media formulation. RoosterBio’s innovative bioprocess media products simply and consistently produce greater than 100 fold expansion of adult stem cells within 8-10 days of culture, while the critical hMSC functional parameters remain intact.
The RoosterBio cell and media systems are the only systems on the market designed for a “batch” culture process, which eliminates the need for labor-intensive and costly media exchanges between passages. These adult stem cell systems are being rapidly adopted by industry participants, and are enabling a new era of efficiency and productivity in the Regenerative Medicine field.
Jon Rowley, CEO of RoosterBio stated:
“Media has always been a regulatory burden and a major cost driver in biomanufacturing processes. RoosterBio’s bioprocess media systems for adult stem cells are driving efficiencies in the field reminiscent of the exponential improvements in monoclonal antibody yields over the last 30 years. We are truly experiencing a paradigm shift in Regenerative Medicine today. The key metric for media productivity is “Millions of Cells produced per Liter of Media”.
Thus, we designed a media focused on optimizing this metric and it has led to significant manufacturing gains. Our cell and media systems provide a 9 fold enhancement in million cells produced per liter of media utilized in culture expansion when compared to the market leading cell and media systems (outlined in our corporate blog), and we have now expanded our product portfolio to include regulatory friendly xeno-free formulations.”
RoosterBio continues to broaden their portfolio of product formats, providing solutions for an extensive range of Regenerative Medicine therapeutic categories. The evolving product offerings enable researchers and product developers to perform small scale screening studies, large scale development studies, and now, clinically-relevant manufacturing bioprocess implementation using the new xeno-free media product.
RoosterBio also offers various adult stem cell product configurations including 1, 10, and 50 million cell vials, with highly engineered bioprocess media systems, as well as pre-assembled working cell banks and kits for rapidly achieving stem cell biomass.
About RoosterBio, Inc.
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
To learn more about the market for stem cell products, view the global strategic report “Stem Cell Research Products – Opportunities, Tools, and Technologies.”